Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

NCT02539849 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-01-31

No results posted yet for this study

Summary

FOS improve gut colonization by Faecalibacterium prausnitzii in patients with Crohn's disease

Conditions

  • Crohn Disease

Interventions

DIETARY_SUPPLEMENT

FOS

DRUG

Adalimumab

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY
  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-12-19
Completion
2017-12-19

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02539849 on ClinicalTrials.gov